BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs. 1999;57:383-408. [PMID: 10193690 DOI: 10.2165/00003495-199957030-00013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Frosio F, Rausa E, Marra P, Boutron-Ruault MC, Lucianetti A. Delayed-release oral mesalamine tablet mimicking a small jejunal gastrointestinal stromal tumor: A case report. World J Clin Cases 2022; 10(19): 6710-6715 [DOI: 10.12998/wjcc.v10.i19.6710] [Reference Citation Analysis]
2 Caviglia GP, De Blasio F, Vernero M, Armandi A, Rosso C, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. J Clin Med 2021;10:4961. [PMID: 34768480 DOI: 10.3390/jcm10214961] [Reference Citation Analysis]
3 Vrettos NN, Wang P, Zhou Y, Roberts CJ, Xu J, Yao H, Zhu Z. In vitro and in vivo evaluation of a sustained-release once-a-day formulation of the novel antihypertensive drug MT-1207. Pharm Dev Technol 2021;26:349-61. [PMID: 33430679 DOI: 10.1080/10837450.2021.1872087] [Reference Citation Analysis]
4 Vernero M, De Blasio F, Ribaldone DG, Bugianesi E, Pellicano R, Saracco GM, Astegiano M, Caviglia GP. The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. J Clin Med 2020;9:E3941. [PMID: 33291846 DOI: 10.3390/jcm9123941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Srinivasa Rao K, Hamza M, Ashok Kumar P, Girija Sravani K. Design and optimization of MEMS based piezoelectric actuator for drug delivery systems. Microsyst Technol 2020;26:1671-9. [DOI: 10.1007/s00542-019-04712-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Nober C, Manini G, Carlier E, Raquez J, Benali S, Dubois P, Amighi K, Goole J. Feasibility study into the potential use of fused-deposition modeling to manufacture 3D-printed enteric capsules in compounding pharmacies. International Journal of Pharmaceutics 2019;569:118581. [DOI: 10.1016/j.ijpharm.2019.118581] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
7 Hong KB, Kim D, Kim BK, Woo SY, Lee JH, Han SH, Bae GU, Kang S. CF₃-Substituted Mollugin 2-(4-Morpholinyl)-ethyl ester as a Potential Anti-inflammatory Agent with Improved Aqueous Solubility and Metabolic Stability. Molecules 2018;23:E2030. [PMID: 30110934 DOI: 10.3390/molecules23082030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Dhingra R, Kedia S, Mouli VP, Garg SK, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Gupta SD, Makharia G, Ahuja V. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission: Predicting relapse in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1698-705. [DOI: 10.1111/jgh.13770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
9 Chen J. Mesalamine-induced nephrotoxicity in the treatment of Crohn disease: a case study. Gastroenterol Nurs 2014;37:70-3. [PMID: 24476836 DOI: 10.1097/SGA.0000000000000026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Scaldaferri F, Petito V, Lopetuso L, Bruno G, Gerardi V, Ianiro G, Sgambato A, Gasbarrini A, Cammarota G. Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm 2013;2013:391473. [PMID: 23737647 DOI: 10.1155/2013/391473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Couto D, Ribeiro D, Freitas M, Gomes A, Lima JL, Fernandes E. Scavenging of reactive oxygen and nitrogen species by the prodrug sulfasalazine and its metabolites 5-aminosalicylic acid and sulfapyridine. Redox Rep. 2010;15:259-267. [PMID: 21208525 DOI: 10.1179/135100010x12826446921707] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
12 Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6. [PMID: 19319380 DOI: 10.1155/2009/501345] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
13 Lakatos PL, Lakatos L. Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis. Orvosi Hetilap 2009;150:397-404. [DOI: 10.1556/oh.2009.28555] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Vidal Á, Gómez-gil E, Sans M, Portella MJ, Salamero M, Piqué JM, Panés J. El papel de la ansiedad y la depresión en las recidivas de la enfermedad inflamatoria intestinal. Medicina Clínica 2009;132:298-302. [DOI: 10.1016/j.medcli.2008.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
15 Tuğcu-demiröz F, Acartürk F, Takka S, Konuş-boyunağa Ö. In-vitro and In-vivo Evaluation of Mesalazine–Guar Gum Matrix Tablets for Colonic Drug Delivery. Journal of Drug Targeting 2008;12:105-12. [DOI: 10.1080/10611860410001693751] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
16 Fernandez-Becker NQ, Moss AC. Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs 2008;68:1089-103. [PMID: 18484800 DOI: 10.2165/00003495-200868080-00006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
17 McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs 2007;67:2635-42. [PMID: 18034594 DOI: 10.2165/00003495-200767170-00010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? A study performed in 30 healthy volunteers. J Clin Pharmacol. 2007;47:334-342. [PMID: 17322145 DOI: 10.1177/0091270006296522] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
19 Mladenovska K, Raicki R, Janevik E, Ristoski T, Pavlova M, Kavrakovski Z, Dodov M, Goracinova K. Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. International Journal of Pharmaceutics 2007;342:124-36. [DOI: 10.1016/j.ijpharm.2007.05.028] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 7.1] [Reference Citation Analysis]
20 Tuğcu-Demiröz F, Acartürk F, Takka S, Konuş-Boyunağa O. Evaluation of alginate based mesalazine tablets for intestinal drug delivery. Eur J Pharm Biopharm 2007;67:491-7. [PMID: 17451926 DOI: 10.1016/j.ejpb.2007.03.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
21 Speisky H, Rocco C, Carrasco C, Lissi EA, López-Alarcón C. Antioxidant screening of medicinal herbal teas. Phytother Res 2006;20:462-7. [PMID: 16619353 DOI: 10.1002/ptr.1878] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
22 Vidal A, Gómez-Gil E, Sans M, Portella MJ, Salamero M, Piqué JM, Panés J. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol 2006;101:775-81. [PMID: 16494590 DOI: 10.1111/j.1572-0241.2006.00476.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
23 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
24 Liu JJ, Zheng CQ, Pan LL, Wen Y, Hu GZ. Experimental research on treatment of ulcerative colitis with integrative traditional Chinese and Western medicine. Shijie Huaren Xiaohua Zazhi 2005; 13(23): 2806-2808 [DOI: 10.11569/wcjd.v13.i23.2806] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Nakashima T, Maeda T, Nagamoto H, Kumakura T, Takai M, Mori T. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig Dis Sci. 2005;50 Suppl 1:S124-S131. [PMID: 16184415 DOI: 10.1007/s10620-005-2817-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
26 Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis. 2005;11:421-427. [PMID: 15867580 DOI: 10.1097/01.mib.0000158386.25660.1e] [Cited by in Crossref: 107] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
27 Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Digestive and Liver Disease 2005;37:381-8. [DOI: 10.1016/j.dld.2004.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
28 Forbes A, Al-damluji A, Ashworth S, Bramble M, Herbert K, Ho J, Kang J, Przemioslo R, Shetty A. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2005;21:1099-104. [DOI: 10.1111/j.1365-2036.2005.02442.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
29 Kumar S, Ghoshal UC, Aggarwal R, Saraswat VA, Choudhuri G. Severe ulcerative colitis: prospective study of parameters determining outcome. J Gastroenterol Hepatol. 2004;19:1247-1252. [PMID: 15482530 DOI: 10.1111/j.1440-1746.2004.03486.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
30 Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5. [PMID: 15365397 DOI: 10.1097/01.mcg.0000140188.88275.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
31 Klotz U, Schwab M. Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:267-79. [PMID: 15555742 DOI: 10.1016/j.addr.2004.08.007] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 5.4] [Reference Citation Analysis]
32 Bitton A, Sewitch MJ, Peppercorn MA, deB Edwardes MD, Shah S, Ransil B, Locke SE. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 2003;98:2203-8. [PMID: 14572569 DOI: 10.1111/j.1572-0241.2003.07717.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 128] [Article Influence: 7.3] [Reference Citation Analysis]
33 Forbes A, Cartwright A, Marchant S, McIntyre P, Newton M. Review article: Oral, modified-release mesalazine formulations--proprietary versus generic. Aliment Pharmacol Ther. 2003;17:1207-1214. [PMID: 12755834 DOI: 10.1046/j.1365-2036.2003.01578.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
34 Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42. [PMID: 12492730 DOI: 10.1046/j.1365-2036.2003.01408.x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 162] [Article Influence: 9.3] [Reference Citation Analysis]
35 McKeage K, Goa KL. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn’s disease in adults. Drugs. 2002;62:2263-2282. [PMID: 12381231 DOI: 10.2165/00003495-200262150-00015] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
36 Nigović B, Šimunić B. Determination of 5-aminosalicylic acid in pharmaceutical formulation by differential pulse voltammetry. Journal of Pharmaceutical and Biomedical Analysis 2003;31:169-74. [DOI: 10.1016/s0731-7085(02)00469-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
37 Jani N, Regueiro MD. Medical therapy for ulcerative colitis. Gastroenterol Clin North Am. 2002;31:147-166. [PMID: 12122729 DOI: 10.1016/s0889-8553(01)00010-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
38 Sandborn WJ. Rational Selection of Oral 5-Aminosalicylate Formulations and Prodrugs for the Treatment of Ulcerative Colitis. American Journal of Gastroenterology 2002;97:2939-41. [DOI: 10.1111/j.1572-0241.2002.07092.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 4.0] [Reference Citation Analysis]
39 Muijsers RB, Goa KL. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs. 2002;62:1689-1705. [PMID: 12109930 DOI: 10.2165/00003495-200262110-00010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gisbert JP, Gomollón F, Maté J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci. 2002;47:471-488. [PMID: 11911332 DOI: 10.1023/A:1017987229718] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 3.7] [Reference Citation Analysis]
41 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2001;40:723-751. [PMID: 11707060 DOI: 10.2165/00003088-200140100-00003] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 4.8] [Reference Citation Analysis]
42 Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20. [PMID: 11208709 DOI: 10.1053/gast.2001.20912] [Cited by in Crossref: 312] [Cited by in F6Publishing: 309] [Article Influence: 14.9] [Reference Citation Analysis]
43 Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, Ganio E, Usai P, Campieri M, Fornaciari G. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther. 2001;15:251-256. [PMID: 11148445 DOI: 10.1046/j.1365-2036.2001.00913.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 2.9] [Reference Citation Analysis]
44 De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet 2000;39:85-97. [PMID: 10976656 DOI: 10.2165/00003088-200039020-00001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
45 Vree TB, Dammers E, Exler PS, Sorgel F, Bondesen S, Maes RA. Upper and Lower Limits in the Renal Clearance of Acetylmesalazine in Humans: Indications for Renal Acetylation of Mesalazine. Clinical Drug Investigation 2001;21:147-56. [DOI: 10.2165/00044011-200121020-00007] [Reference Citation Analysis]
46 Vree TB, Dammers E, Exler PS, Maes RA. Multiple Absorption Patterns of Mesalazine from Two Gastroresistant Tablets in Healthy Male Volunteers: Effects of Food and Formulation. Clinical Drug Investigation 2001;21:295-305. [DOI: 10.2165/00044011-200121040-00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Vree TB, Dammers E, Exler PS, Maes RA. Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosing. J Pharm Pharmacol 2000;52:645-52. [PMID: 10875540 DOI: 10.1211/0022357001774471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
48 Sutherland LR. Prevention of Relapse of Crohnʼs Disease: . Inflammatory Bowel Diseases 2000;6:321-8. [DOI: 10.1097/00054725-200011000-00009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
49 Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut. 2000;47:410-414. [PMID: 10940280 DOI: 10.1136/gut.47.3.410.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Frieri G, Giacomelli R, Pimpo M, Palumbo G, Passacantando A, Pantaleoni G, Caprilli R. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000;47:410-4. [PMID: 10940280 DOI: 10.1136/gut.47.3.410] [Cited by in Crossref: 101] [Cited by in F6Publishing: 89] [Article Influence: 4.6] [Reference Citation Analysis]
51 Vree TB, Dammers E, Exler PS, S??rgel F, Maes RA. Saturable Active Tubular Reabsorption in the Renal Clearance of Mesalazine in Human Volunteers: . Clinical Drug Investigation 2000;20:35-42. [DOI: 10.2165/00044011-200020010-00005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]